Related Experiment Videos
Albuterol in acute bronchiolitis--continued therapy despite poor response?
R A Lugo1, J W Salyer, J M Dean
1Department of Pharmacy Practice, University of Utah College of Pharmacy, Salt Lake City 84112, USA.
Pharmacotherapy
|February 20, 1998
Summary
Many clinicians continue nebulized albuterol for acute bronchiolitis even without improvement. This ineffective treatment persists through hospitalization and after discharge, leading to unnecessary costs.
Area of Science:
- Pediatrics
- Respiratory Medicine
Background:
- Acute bronchiolitis is a common respiratory infection in infants.
- Nebulized albuterol is frequently used, but its efficacy is debated.
Purpose of the Study:
- To evaluate the continued use of nebulized albuterol in acute bronchiolitis despite a lack of clinical improvement.
Main Methods:
- Retrospective review of medical records for 90 infants and children diagnosed with acute bronchiolitis.
- Defined clinical improvement based on respiratory parameters post-treatment.
- Assessed albuterol continuation orders and documentation of response.
Main Results:
- 52% of patients receiving nebulized albuterol showed no documented clinical improvement in the emergency department.
- Despite lack of improvement, 94% had orders to continue therapy upon admission.
- 61% continued to show no improvement within 12 hours of admission.
- 87% of non-responders received albuterol throughout hospitalization, and 54% post-discharge.
Conclusions:
- Nebulized albuterol is often continued for acute bronchiolitis despite evidence of no clinical benefit.
- This practice leads to unnecessary treatment and increased medical expenses.